SS Innovations International Inc. (NASDAQ: SSII) announced record first-quarter 2026 financial results, with revenue reaching $11.1 million, a 116.8% increase year over year. The growth was primarily driven by higher installations of the SSi Mantra surgical robotic system and increased procedure volumes, according to the company's earnings announcement.
The installed base of SSi Mantra systems grew to 194 across 11 countries, with cumulative robotic procedures nearing 9,750. As of June 22, 2026, the cumulative number of multi-specialty procedures completed with the system totaled 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Additionally, approximately 2,100 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of procedures.
Regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines expanded the company’s international market access during the quarter. The company also completed the world’s longest-distance robotic cardiac telesurgery in history, demonstrating the capabilities of its remote surgery platform.
SS Innovations continues pursuing regulatory clearance in both the United States and Europe while expanding its presence in emerging healthcare markets. Gross profit rose to $5.3 million from $1.1 million a year earlier. For more information, visit the company’s website at www.SSInnovations.com.
This announcement underscores the accelerating commercial adoption of surgical robotics and the potential for telesurgery to expand access to specialized care. The company’s ability to secure regulatory approvals in multiple countries and perform groundbreaking telesurgeries positions it as a key player in the global surgical robotics market.
